Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Xediton Pharmaceuticals","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn and Xediton Sign Exclusive License and Distribution Agreement for TRUSELTIQ\u2122 (Infigratinib) in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Xediton Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Xediton Pharmaceuticals

    Menu

    Xediton Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Xediton Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada

              Details:

              Under the terms of the agreement, Xediton is responsible for the registration and commercialization of BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products in Canada.

              Lead Product(s): Delafloxacin

              Therapeutic Area: Infections and Infectious Diseases Product Name: Baxdela

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Melinta Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement May 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Xediton Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Helsinn and Xediton Sign Exclusive License and Distribution Agreement for TRUSELTIQ™ (Infigratinib) in Canada

              Details:

              Under the terms of the license and distribution agreement, Helsinn Healthcare SA grants Xediton an exclusive license to distribute, promote, market, and sell TRUSELTIQ in Canada and Helsinn will supply TRUSELTIQ for commercialization in Canada.

              Lead Product(s): Infigratinib

              Therapeutic Area: Oncology Product Name: Truseltiq

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Helsinn Advanced Synthesis

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY